Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | KDM6B | O15054 | 4/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 11/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420988 | 0.89 | ALDH1A1 (0.44) | CDK1TDP1KDM4EMEN1ALDH1A1 | |
| SCHEMBL4416406 | 0.84 | KDM4E (0.44) | KDM6BGRM2TDP1KDM4EMEN1 | |
| SCHEMBL4412348 | 0.84 | ALDH1A1 (0.41) | GRM2KDM4EMEN1ALDH1A1GLA | |
| SCHEMBL4412497 | 0.83 | PDE4A (0.43) | KDM6BGRM2TDP1KDM4EALDH1A1 | |
| SCHEMBL4416743 | 0.80 | GRM2 (0.42) | KDM6BGRM2TDP1KDM4EMEN1 | |
| SCHEMBL4417537 | 0.79 | GRM2 (0.42) | KDM6BGRM2TDP1MEN1GAA | |
| SCHEMBL4412351 | 0.78 | GRM2 (0.42) | KDM6BGRM2KDM4EMEN1ALDH1A1 | |
| SCHEMBL4420345 | 0.77 | ALDH1A1 (0.42) | GRM2KDM4EMEN1ALDH1A1GLA | |
| SCHEMBL4416954 | 0.76 | CDK1 (0.37) | CDK1TDP1KDM4EALDH1A1MAPT | |
| SCHEMBL27604213 | 0.76 | MKNK1 (0.41) | KDM6BGRM2TDP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397351-B1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| CN-1245391-C | Pyrimidine, Triazine and pyrazine derivatives as glutamate receptors | HOFFMANN LA ROCHE (CH) | 2006-03-15 | — | — | CN | disclosed |
| CN-1512988-A | Pyrimidine, Triazine and pyrazine derivatives as glutamate receptors | - | 2004-07-14 | — | — | CN | disclosed |
| US-6673795-B2 | SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030060466-A1 | Pyrimidine, pyrazine and triazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060466-A1 | Pyrimidine, pyrazine and triazine derivatives | P2RX5, IL5, P2RX2 | CDK1 647/4885KDM6B 3959/4885GRM2 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.